Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tailored transplant doses aim to beat blood cancer

NCT ID NCT06028828

Recruiting now Disease control Sponsor: University of California, Irvine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a personalized approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Instead of a one-size-fits-all chemotherapy and radiation regimen, doctors adjust the doses based on each patient's risk. The goal is to improve the chance of staying cancer-free without serious side effects. The study enrolls 60 adults aged 18-70 who have a suitable donor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fludarabine, Melphalan, and Total Body Irradiation
What this could lead to
If successful, this could lead to a more personalized stem cell transplant approach that reduces relapse and improves survival for blood cancer patients.
What could go wrong
This is a small, early-phase trial with only 60 participants. The risk-adapted approach may not improve outcomes and could increase side effects like graft-versus-host disease or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia B-cell chronic lymphocytic leukemia chronic myelogenous leukemia, BCR-ABL1 positive classic Hodgkin lymphoma hematopoietic and lymphoid system neoplasm myelodysplastic syndrome non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ALLOGENEIC STEM CELL TRANSPLANTATION HEMATOLOGIC MALIGNANCIES

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Chao Family Comprehensive Cancer Center, University of California Irvine

    RECRUITING

    Orange, California, 92868, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.